NASDAQ:CRMD CorMedix (CRMD) Stock Price, News & Analysis $4.54 -0.17 (-3.61%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$4.52▼$4.7950-Day Range$4.12▼$5.3652-Week Range$2.57▼$7.00Volume357,577 shsAverage Volume528,220 shsMarket Capitalization$249.51 millionP/E RatioN/ADividend YieldN/APrice Target$12.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get CorMedix alerts: Email Address CorMedix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside175.3% Upside$12.50 Price TargetShort InterestBearish18.85% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.02Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.85) to ($0.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.77 out of 5 starsMedical Sector843rd out of 936 stocksPharmaceutical Preparations Industry396th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingCorMedix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCorMedix has only been the subject of 2 research reports in the past 90 days.Read more about CorMedix's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted18.85% of the outstanding shares of CorMedix have been sold short.Short Interest Ratio / Days to CoverCorMedix has a short interest ratio ("days to cover") of 19.5, which indicates bearish sentiment.Change versus previous monthShort interest in CorMedix has recently increased by 5.61%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCorMedix does not currently pay a dividend.Dividend GrowthCorMedix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRMD. Previous Next 1.7 News and Social Media Coverage News SentimentCorMedix has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for CorMedix this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for CRMD on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat Follows1 people have added CorMedix to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CorMedix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.60% of the stock of CorMedix is held by insiders.Percentage Held by InstitutionsOnly 34.18% of the stock of CorMedix is held by institutions.Read more about CorMedix's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CorMedix are expected to grow in the coming year, from ($0.85) to ($0.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CorMedix is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CorMedix is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorMedix has a P/B Ratio of 3.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CorMedix's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."Click here to see why Wall Street is in PANIC mode >>> About CorMedix Stock (NASDAQ:CRMD)CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Read More CRMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRMD Stock News HeadlinesJuly 19, 2024 | msn.comScilex Holding files to sell up to 3.5M shares by holdersJuly 3, 2024 | globenewswire.comCorMedix Inc. Announces Outpatient Availability of DefenCathJuly 27, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…June 6, 2024 | globenewswire.comCorMedix Inc. Announces CMS Grants Pass-Through Status to DefencathMay 28, 2024 | markets.businessinsider.comCorMedix Secures Strong Market Position with Successful DefenCath Launch and Strategic Supply AgreementsMay 28, 2024 | globenewswire.comCorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis ProviderMay 13, 2024 | finance.yahoo.comCorMedix Inc. (NASDAQ:CRMD) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comCorMedix Inc. (CRMD) Q1 2024 Earnings: Net Loss Widens, Misses Analyst ForecastsJuly 27, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…May 10, 2024 | globenewswire.comCorMedix Inc. to Participate in Two Upcoming Investor ConferencesMay 9, 2024 | msn.comCRMD Stock Earnings: Cormedix Beats EPS for Q1 2024May 9, 2024 | globenewswire.comCorMedix Inc. Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 6, 2024 | globenewswire.comCorMedix Inc. To Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 9, 2024April 20, 2024 | investing.comCorMedix product 'DefenCath' gains CMS transitional payment statusApril 20, 2024 | finanznachrichten.deCorMedix, Inc.: CorMedix Inc. Announces CMS Grants TDAPA to DefenCathApril 19, 2024 | marketwatch.comCorMedix Shares Rise 6% After DefenCath Meets Payment CriteriaApril 19, 2024 | globenewswire.comCorMedix Inc. Announces CMS Grants TDAPA to DefenCathApril 15, 2024 | investorplace.comBiotech on a Budget: 7 Stocks Under $10 With Huge PotentialSee More Headlines Receive CRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRMD CUSIPN/A CIK1410098 Webwww.cormedix.com Phone(908) 517-9500Fax908-429-4307Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$12.50 High Stock Price Target$19.00 Low Stock Price Target$9.00 Potential Upside/Downside+175.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-77.17% Return on Assets-67.31% Debt Debt-to-Equity RatioN/A Current Ratio6.65 Quick Ratio6.41 Sales & Book Value Annual Sales$60,000.00 Price / Sales4,158.64 Cash FlowN/A Price / Cash FlowN/A Book Value$1.28 per share Price / Book3.55Miscellaneous Outstanding Shares54,960,000Free Float52,980,000Market Cap$249.52 million OptionableOptionable Beta1.60 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Joseph Todisco MBA (Age 47)CEO & Director Comp: $1.07MDr. Matthew T. David M.D. (Age 45)Executive VP & CFO Comp: $597.27kMs. Erin Mistry (Age 41)Executive VP & Chief Commercial Officer Comp: $561.57kMs. Elizabeth Masson-Hurlburt B.A. (Age 44)Executive VP and Chief Clinical Strategy & Operations Officer Comp: $538.91kMs. Kaufman Beth Zelnick Esq.Executive VP, Chief Legal Officer & Corporate SecretaryDonna UcciSenior VP & Head of Global QualityDr. Tushar MukherjeeSenior VP & Head of Technical OperationsMore ExecutivesKey CompetitorsAquestive TherapeuticsNASDAQ:AQSTNature's Sunshine ProductsNASDAQ:NATRChiasmaNASDAQ:CHMABlack Diamond TherapeuticsNASDAQ:BDTXSolid BiosciencesNASDAQ:SLDBView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 25,677 shares on 7/26/2024Ownership: 0.289%Virtu Financial LLCSold 16,582 shares on 5/20/2024Ownership: 0.020%Tidal Investments LLCBought 14,105 shares on 5/17/2024Ownership: 0.026%Wick Capital Partners LLCSold 44,000 shares on 5/15/2024Ownership: 0.136%Price T Rowe Associates Inc. MDBought 2,562 shares on 5/15/2024Ownership: 0.027%View All Insider TransactionsView All Institutional Transactions CRMD Stock Analysis - Frequently Asked Questions How have CRMD shares performed this year? CorMedix's stock was trading at $3.76 on January 1st, 2024. Since then, CRMD shares have increased by 20.7% and is now trading at $4.54. View the best growth stocks for 2024 here. How were CorMedix's earnings last quarter? CorMedix Inc. (NASDAQ:CRMD) announced its quarterly earnings data on Thursday, May, 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.02. When did CorMedix's stock split? CorMedix shares reverse split on Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. Who are CorMedix's major shareholders? Top institutional shareholders of CorMedix include Bank of New York Mellon Corp (0.29%). Insiders that own company stock include Myron Kaplan and Matthew T David. View institutional ownership trends. How do I buy shares of CorMedix? Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of CorMedix own? Based on aggregate information from My MarketBeat watchlists, some other companies that CorMedix investors own include Amarin (AMRN), NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gigamon (GIMO), Conatus Pharmaceuticals (CNAT), Nabriva Therapeutics (NBRV) and QUALCOMM (QCOM). This page (NASDAQ:CRMD) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CorMedix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CorMedix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRMD Stock Alerts